Ribavirin

• CAT Number: A000398
• CAS Number: 36791-04-5
• Molecular Formula: C8H12N4O5
• Molecular Weight: 244.2
• Purity: ≥95%
• Synonyms: 36791-04-5; Tribavirin; Virazole; Ribavirine; Copegus
• Storage: -20°C
• IUPAC Name: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
• InChI: InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
• InChIKey: IWUCXVSUMQZMFG-AFCXAGJDSA-N
• SMILES: C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N

Ribavirin (CAS 36791-04-5) is an anti-viral drug used for severe RSV infection; hepatitis C infection, including if persistent, and often in combination with peginterferon alfa-2b or peginterferon alfa-2a; as well as some other viral infections. It is a guanosine (ribonucleic) analog used to stop viral RNA synthesis and viral mRNA capping, thus, it is a nucleoside inhibitor. Ribavirin is a prodrug, which when metabolized resembles purine RNA nucleotides. In this form it interferes with RNA metabolism required for viral replication. How it exactly affects viral replication is unknown; many mechanisms have been proposed for this but none of these has been proven to date. Multiple mechanisms may be responsible for its actions.

Overview of Clinical Research

Ribavirin is a nucleic acid inhibitor. It is marketed to treat Hepatitis C.

Reference

1: Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027. [Epub ahead of print] PubMed PMID: 29120906.
2: Tan J, Ye J, Song M, Zhou M, Hu Y. Ribavirin augments doxorubicin/'s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2017 Nov 7. doi: 10.1002/jbt.22007. [Epub ahead of print] PubMed PMID: 29112301.
3: Garcia B, Sharma N, Johnson K, Salgado J, Wille K. Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series. Exp Clin Transplant. 2017 Oct 31. doi: 10.6002/ect.2017.0133. [Epub ahead of print] PubMed PMID: 29108516.
4: Waldenström J, Lagging M. Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1115-1116. doi: 10.1111/apt.14354. PubMed PMID: 29105131.
5: Nakamoto S, Imazeki F, Kanda T, Wu S, Nakamura M, Yasui S, Tawada A, Mikata R, Chiba T, Arai M, Yokosuka O, Shirasawa H. Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. Int J Med Sci. 2017 Sep 4;14(11):1088-1093. doi: 10.7150/ijms.20171. eCollection 2017. PubMed PMID: 29104462; PubMed Central PMCID: PMC5666539.
6: Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS, Yu ML. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc. 2017 Oct 30. pii: S0929-6646(16)30474-0. doi: 10.1016/j.jfma.2017.10.001. [Epub ahead of print] PubMed PMID: 29097076.
7: de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. Clin Infect Dis. 2017 Oct 25. doi: 10.1093/cid/cix916. [Epub ahead of print] PubMed PMID: 29077864.
8: Danilau D, Malich N, Litvinchuk D, Karpov I. Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus. Clin Exp Hepatol. 2017 Sep;3(3):164-168. doi: 10.5114/ceh.2017.70281. Epub 2017 Sep 25. PubMed PMID: 29062907; PubMed Central PMCID: PMC5649486.
9: Jia YT, Duan XH, Yang ZX, Su YH. [Association of interleukin-28B and interferon-lambda 4 gene polymorphisms with response to pegylated interferon plus ribavirin antiviral treatment for chronic hepatitis C patients]. Zhonghua Gan Zang Bing Za Zhi. 2017 Jul 20;25(7):529-532. doi: 10.3760/cma.j.issn.1007-3418.2017.07.011. Chinese. PubMed PMID: 29055993.
10: Seo K, Kim SK, Kim SR, Ohtani A, Kobayashi M, Kato A, Morimoto E, Saijo Y, Kim KI, Imoto S, Kim CW, Yano Y, Kudo M, Hayashi Y. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. Dig Dis. 2017;35(6):541-547. doi: 10.1159/000480145. Epub 2017 Oct 17. PubMed PMID: 29040986.